NERV · Minerva Neurosciences, Inc.

Minerva Neurosciences' first quarter 2026 results are dominated by significant non-cash accounting charges that obscure the underlying operational performance. The company reported a substantial GAAP net loss of $125.4 million, or $2.86 per share, a sharp increase from the $3.8 million loss in the prior-year period. This result was primarily driven by a $109.4 million non-cash expense related to the change in fair value of warrant liability and losses recognized upon warrant exercises. Additionally, G&A expenses surged to $11.4 million, largely due to a one-time $6.6 million stock compensation charge associated with the settlement agreement for the departing President, Geoff Race. Stripping out these non-cash items, the non-GAAP adjusted net loss was $7.3 million, or $0.17 per share, which aligned with analyst consensus estimates.

Operationally, the quarter marked a pivotal transition for the company. Minerva initiated its global confirmatory Phase 3 trial (MIN-101C19) for roluperidone, targeting negative symptoms of schizophrenia, and screened the first patient in March 2026. The trial aims to enroll approximately 380 patients across 40 sites, with topline data expected in the second half of 2027. R&D expenses increased to $5.3 million, reflecting the costs of this trial initiation. The company maintains a cash position of $78.2 million, providing a runway to execute this critical study. Leadership changes were also announced, with Jim O'Connor joining as Chief Business Officer and General Counsel. The divergence between GAAP and non-GAAP results highlights the volatility introduced by the company's warrant structure and equity compensation, while the clinical progress underscores the binary nature of the investment thesis centered on the Phase 3 outcomes.